OTC · Health care

Cell Source, Inc. (CLCS)

It posted a net loss of $4.7M. At March 31, 2025 it held $1.2K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on May 14, 2026.

Watch CLCS in 60 seconds

Price

$0.42

-9.19% on the day · September 25, 2026

52-week range $0.25 to $2.25

Market cap

$28.5M

What Cell Source, Inc. does

Cell Source, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker CLCS.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2024	n/a	-$3.8M	-$4.5M	-$0.14	n/a
2023	n/a	-$4.3M	-$5.3M	-$0.17	n/a
2022	n/a	-$4.2M	-$5.2M	-$0.18	n/a
2021	n/a	-$4M	-$5.5M	-$0.19	n/a
2020	n/a	-$3.6M	-$4.6M	-$0.19	n/a
2019	n/a	-$3.8M	-$4.5M	-$0.18	n/a

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Cell Source, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

May 14, 2026
Quarterly report 10-Q · period to March 31, 2025Diluted EPS -$0.04 versus -$0.04.
April 7, 2026
Annual report 10-K · period to December 31, 2024Diluted EPS -$0.14 versus -$0.17.
July 16, 2025
Deregistration 15-12G
June 27, 2025
Auditor change 8-K
March 28, 2025
Late annual report notice NT 10-K
November 14, 2024
Quarterly report 10-Q · period to September 30, 2024Diluted EPS -$0.04 versus -$0.04.
August 19, 2024
Quarterly report 10-Q · period to June 30, 2024Diluted EPS -$0.04 versus -$0.04.
August 14, 2024
Late quarterly report notice NT 10-Q
July 29, 2024
Quarterly report 10-Q · period to March 31, 2024Diluted EPS was -$0.04.
June 24, 2024
Annual report 10-K · period to December 31, 2023Diluted EPS -$0.17 versus -$0.18.

Recent insider filings (Forms 3, 4 and 144): 10, the latest on April 21, 2022. Insider transactions on SEC

All filings on SEC EDGAR

Questions about CLCS

What does Cell Source, Inc. do?

Cell Source, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on OTC under the ticker CLCS.

Is Cell Source, Inc. profitable?

No. Over the twelve months to March 31, 2025 it reported a net loss of $4.7M.

When did Cell Source, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on May 14, 2026. It covers the period to March 31, 2025.

Similar companies

TAK

Takeda Pharmaceutical Co Ltd

Compare CLCS with

Compare CLCS with any company

Follow CLCS

Get an email when Cell Source, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CLCS: get an email when it files

Where the numbers come from

Financial figures are the values Cell Source, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.